<DOC>
	<DOC>NCT00385554</DOC>
	<brief_summary>This study will test the safety, side effects, and acceptability of two strengths of UC-781 gel when used by women and men in Botswana for two weeks.</brief_summary>
	<brief_title>Botswana Study of UC-781 Vaginal Microbicide</brief_title>
	<detailed_description>45 women and 45 men, all healthy and sexually active, 21-45 years old, without HIV infection, will be enrolled in Francistown and Gaborone, Botswana. Volunteers will be randomized to receive either 0.1% or 0.25% UC-781 carbomer gel or placebo gel (3 arms. Women will be instructed to apply gel intravaginally, morning and evening, and prior to sex (always with male condom use) for 14 consecutive days. Men will be instructed to apply gel topically for 14 consecutive nights, before bed, allow to dry overnight, and wash it off in the morning. Additionally instructed never to use gel during sex but always to use condoms. Volunteers will be seen weekly for evaluation of symptoms, laboratory toxicities, genital exam findings (with colposcopy for women, and plasma drug levels. Acceptability will be assessed in focus groups in the month after completing gel use.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>2145 years old citizen of Botswana willing to use condoms for 14 days PAP smear (normal, inflammation, ASCUS) regular menses or amenorrhea lives within 1 hour of a study clinic pass comprehension test provide written informed consent genital mucosal disruption at screening genital surgery within past 8 weeks pregnant within past 8 weeks currently breastfeeding prior hysterectomy plans to move within 2 months ALT, AST, total bilirubin, or creatinine Grade 2 or above Prothrombin or partial thromboplastin time Grade 2 or above In other drug/vaccine safety trial Has more than one sexual partner in past month Unwilling/unsure they can have sex at least twice weekly for 2 weeks Any other condition that investigator believes will interfere with the evaluation of study objectives</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>HIV prevention</keyword>
	<keyword>Botswana</keyword>
	<keyword>Preventing acquisition of HIV infection</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>